Blue Channel | Stock Market News & Stocks to Watch from StraightStocks

FDA Play: Redefining Breast Cancer Detection (OTC:LLBO)

Michael Vlaicu (September 18th, 2009) Writes:

Lifeline Biotechnologies Inc.

(Public, PINK:LLBO)

With the recent gains in Hard to Treat Diseases Inc. (PINK:HTDS) and BioElectronics Corp. (OTC:BIEL), investors were left hungry for more undervalued, high potential biotech companies — Then came LifeLine Biotechnologies Inc (OTC:LLBO). As technology continues to redefine the modern era of medical advancements, certain companies will stand apart from the rest, as is the case with Lifeline Biotechnologies Inc. This company is an innovative medical technology company committed to the improvement of the quality of life through exceptional health care systems, focusing on prevention, early diagnosis, and quick recovery. Recently, the company has made headlines with their innovative Breast Cancer detection system, the First Warning System ™, a dynamic test which collects information over time with an uncanny efficacy. The next several months will prove to be critical for LifeLine Biotechnologies, as they await the FDA’s decision

...

Tags for this Post:
achieved technology levels, BioElectronics Corp., Blue channel, breast biopsy products, Breast Cancer, breast cancer detection products, breast cancers, cancer, cancer detection system, cancer detection;, Cancers, care physician, cent;, ceo, computer software, conventional and digital mammography systems, detection systems, Diagnostic Products, Fda, health care systems;, Investing Lessons, Jim Holmes, Lifeline Biotechnologies Inc., magnetic resonance imaging, magnetic resonance imaging products, medical technology, Michael Vlaicu;, Nevada, non-breast-specific diagnostic technologies, non-imaging, non-imaging technology, nuclear imaging products, ovarian cancer, Peaceful Trading - Vlad Moraru, pharmacogenetic and prognostic testing products, physician, Reno, stage disease, Stocks to Watch, susceptibility testing products, technology advances;, Treat Diseases Inc., treatment of breast cancer, tumor, tumors, ultrasound, ultrasound products, United States, USD, various disease, What am;

Posted in Investing Lessons, Stocks to Watch | No Comments »

Taking Cancer Treatment to a New Level (OTC:PVCT)

Michael Vlaicu (September 16th, 2009) Writes:

Provectus Pharmaceuticals, Inc.

(Public, OTC:PVCT)

StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer, one of the largest target markets worldwide and seeking “compassionate use” in Australia and USA, look for Provectus to make a splash within the next couple of months.

They are developing and testing one of the most exciting anti- cancer compounds. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a

...

Tags for this Post:
actress, American Society of Clinical Oncology;, Analyst, and plans to sell, and plans to sell products, Atopic Dermatitis, Australia, Biopharmaceutical, Blue channel, Bob Marley;, Breast Cancer, cancer, Cancer of the skin, Cancers, cent;, Cybill Shepherd, device systems, Elizabeth Taylor, Eva Cassidy, Fda, FDA protocol, Florida, Healthcare Industry, invasive products, John F. Thompson, john mccain, lead investigator, Liver Cancer, malignant melanomas, Melanoma, Michael Vlaicu;, New York City, Orlando, owned subsidiaries, prescription drug products, Professor, Provectus Biotech Inc., Provectus Devicetech Inc., Provectus Imaging Inc. IP, Provectus Pharmaceuticals Inc., Provectus Pharmatech Inc., psoriasis, PURE;, PV-10, Ronald Reagan, Sam Donaldson, skin cancer, skin cancers, Stocks to Watch, surgery, thin tumours, treatment for melanoma, treatment of psoriasis, tumor, tumors, United States, USD, World Health Organization, Xantech Pharmaceuticals Inc., Yahoo

Posted in Stocks to Watch | No Comments »

New Pain Treatment Triumphs Morphine (OTC:NPHC)

Michael Vlaicu (September 11th, 2009) Writes:

Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

...